This website is for UK Healthcare Professionals only

This promotional website is for UK healthcare professionals involved in the care of patients with ovarian cancer.

This promotional website is for UK healthcare professionals involved in the care of patients with ovarian cancer.

You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for ELAHERE. Adverse event reporting information is at the bottom of this page.

 
1. ELAHERE SmPC

UK-ELAH-260244. Date of Preparation: August 2026

You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for ELAHERE. Adverse event reporting information is at the bottom of this page.

1. ELAHERE SmPC

UK-ELAH-260244. Date of Preparation: August 2026

UK-ELAH-260246. Date of Preparation: August 2026

Contact us

Please complete the form below and a member of the ELAHERE®▼ (mirvetuximab soravtansine) team will get back to you.

Please fill in your details below only if you are a UK registered healthcare professional and would like to contact an AbbVie representative.

ELAHERE® as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.1

Eligible patients should have FRα tumour status defined as ≥75% viable tumour cells demonstrating moderate (2+) and/or strong (3+) membrane staining by immunohistochemistry.1

Please enter First name
Please enter Last name
Please enter Role
E-mail address is not valid
Please enter Last name
Please enter Hospital name
Please enter hospital postcode
Please select a field.
Please select one field.


Please refer to the AbbVie privacy notice here for more information on how AbbVie processes your personal data and your data privacy rights.

*Denotes mandatory field

Incorrect. Please try again.

References:

1. ELAHERE® Summary of Product Characteristics.

References:

1. ELAHERE® Summary of Product Characteristics.

 

Please refer to the ELAHERE® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The ELAHERE® Summary of Product Characteristics can be found here.

By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

UK-ELAH-260297. Date of preparation: October 2026.